Sequence Information

    • DRAMP ID

    • DRAMP20761

    • Name

    • LTX-109

    • Sequence

    • R-Tbt-R-NH-EtPh

    • Description

    • LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis.

    • Activity

    • Antibacterial

    • Target Organism

      • [Ref.22585222]Gram-positive bacteria:
        Methicillin-resistant Staphylococcus aureus(MRSA) (MIC=2-4 μg/ml; MBC=2-8 μg/ml), Vancomycin-intermediate Staphylococcus aureus(VISA) (MIC=2-4 μg/ml; MBC=2-8 μg/ml), Vancomycin-resistant Staphylococcus aureus(VRSA) (MIC=2-4 μg/ml; MBC=2-4 μg/ml), Daptomycin-nonsusceptible Staphylococcus aureus(DNSSA) (MIC=2-4 μg/ml; MBC=2-8 μg/ml), Linezolid-nonsusceptible S. aureus (LNSSA) (MIC=4 μg/ml; MBC=4 μg/ml)

    • Reference

      • LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus. Antimicrob Agents Chemother. 2015.(PMID: 25331699)
      • In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.Antimicrob Agents Chemother. 2012.(PMID: 22585222)

Clinical Information

    • Medical use

    • Uncomplicated Gram positive skin infections, impetigo,and nasal colonization with S. aureus

    • Company

    • Lytix Biopharma AS

    • Stage of Development

    • Phase I/II

    • Comments

    • This is a pilot study conducted to evaluate the safety, local tolerability and efficacy of LTX-109(Lytixar?), a lytic peptide designed to kill bacterias quickly and efficient. LTX-109 (Lytixar?)will be applied in the anterior nares in subjects who are carriers of nasal colonies of MRSA/MSSA.The extent of systemic absorption of LTX -109 when applied to the anterior nares will be evaluated and the effect of Lytixar? as to clear colonies of MRSA/MSSA during the the observation period and Week 2 to Week 9 after treatment. (ClinicalTrials.gov Identifier: NCT01158235)

    • Clinical Trials

    • NCT01223222
    • NCT01803035
    • NCT01158235